Antibodies against insulin-like growth factor i receptor and uses thereof
CA 2519113 C · Owner: Van De Winkel, Jan · Inventors: Schumacher, Ralf; Van De Winkel, Jan; Rebers, Frank
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IG-RI which is characterized in that said antibody is of human IgG1 isotype, and shows a ratio of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-IR of 1:3 to 3:1 and induces celle , death of 20% or more cells of a preparation of IGF-IR expressing cells after 24 hours at a concentration of said antibody of 100 nM by ADCC; has improved properties in antitumor therapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 1, 2004 and granted June 5, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 1, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 1, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.